Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial
comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with
head and neck cancer following surgery. Lapatinib or placebo will be administered
post-operatively in combination with chemoradiotherapy followed by maintenance with
lapatinib or placebo for 1 year. The primary goal is to determine if lapatinib is effective
at reducing the recurrence of the disease in these high-risk patients.